Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate

Journal of Bone and Mineral Research

Volumn 24, Issue 4, 2009, Pages 669-674

  Cheung, Moira S ^a   Glorieux, Francis H ^a   Rauch, Frank ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b SHRINERS HOSPITAL FOR CHILDREN   (Canada)

Author keywords

Bisphosphonates; Children; Osteoclasts; Osteogenesis imperfecta

Indexed keywords

CALCIUM; COLLAGEN TYPE 1; PAMIDRONIC ACID; VITAMIN D;

ADOLESCENT; ARTICLE; BIOCHEMISTRY; BONE DENSITY; CANCELLOUS BONE; CELL COUNT; CELL NUCLEUS; CELL SIZE; CELL STRUCTURE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; ILIAC BONE; LUMBAR SPINE; MALE; MULTIPLE CYCLE TREATMENT; MUTATION; OCCUPATIONAL THERAPY; OSTEOCLAST; OSTEOGENESIS IMPERFECTA; PHYSIOTHERAPY; PRESCHOOL CHILD; SCHOOL CHILD; VITAMIN SUPPLEMENTATION;

ADOLESCENT; ANTHROPOMETRY; BONE DENSITY CONSERVATION AGENTS; CHILD; CHILD, PRESCHOOL; DENSITOMETRY; DIPHOSPHONATES; FEMALE; HUMANS; ILIUM; INFANT; INJECTIONS, INTRAVENOUS; MALE; OSTEOCLASTS; OSTEOGENESIS IMPERFECTA;

EID: 65549120679     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.081225     Document Type: Article

References (17)

1. Rauch F, Glorieux FH 2004 Osteogenesis imperfecta. Lancet 363:1377-1385.
2. Arikoski P, Silverwood B, Tillmann V, Bishop NJ 2004 Intravenous Pamidronate treatment in children with moderate to severe osteogenesis imperfecta: Assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone 34:539-546.
3. Astrom E, Soderhall S 2002 Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 86:356-364.
4. Russell RG 2007 Bisphosphonates: Mode of action and pharmacology. Pediatrics 119(Suppl 2):S150-S162.
5. Halasy-Nagy JM, Rodan GA, Reszka AA 2001 Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 29:553-559.
6. Schenk R, Merz WA, Muhlbauer R, Russell RG, Fleisch H 1973 Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (C1 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 11:196-214.
7. Fisher JE, Rodan GA, Reszka AA 2000 In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 141:4793-4796.
8. Rauch F. Travers R, Plotkin H, Glorieux FH 2002 The effects of intravenous Pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:1293-1299.
9. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S 2003 Bisphosphonate-induced osteopetrosis. N Engl J Med 349:457-463.
10. Glorieux FH, Travers R, Taylor A, Bowen JR. Rauch F, Norman M, Parfitt AM 2000 Normative data for iliac bone histomorphometry in growing children. Bone 26:103-109.
11. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610.
12. Ogden CL, Kuczmarski RJ, Flegal KM. Mei Z, Guo S, Wei R, Grummer-Strawn LM, Curtin LR, Roche AF, Johnson CL 2002 Centers for Disease Control and Prevention 2000 growth charts for the United States: Improvements to the 1977 National Center for Health Statistics version. Pediatrics 109:45-60.
13. Salle BL, Braillon P, Glorieux FH, Brunet J, Cavero E, Meunier PJ 1992 Lumbar bone mineral content measured by dual energy X-ray absorptiometry in newborns and infants. Acta Paediatr 81:953-958.
14. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH 2003 Osteogenesis imperfecta types I, III, and IV: Effect of Pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88:986-992.
15. Rauch F, Travers R, Munns C, Glorieux FH 2004 Sclerotic metaphyseal lines in a child treated with Pamidronate: Histomorphometric analysis. J Bone Miner Res 19:1191-1193.
16. Land C, Rauch F, Glorieux FH 2006 Cyclical intravenous Pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res 21-374-379.
17. Reszka AA, Rodan GA 2004 Nitrogen-containing bisphos- phonate mechanism of action. Mini Rev Med Chem 4:711-719.